HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA ‘Closer To Zero’ Meeting On Infant Nutrition Safety And Benefits Set For November

Executive Summary

CFSAN launched “C2Z” initiative in April following widespread reports of contamination of baby food products. Agency officials will outline C2Z plan including a four-stage approach for continual improvement and additional work related to levels of toxic elements in food.

You may also be interested in...



Abbott Recalls Infant Formula Made At Facility FDA Is Investigating For Bacterial Contamination

Abbott Labs recalls Similac, Alimentum and EleCare brand formula powders made at Sturgis, MI, plant. FDA says complaints about Abbott’s formulas included three reports of Cronobacter sakazakii infections, with one death potentially linked, and one of Salmonella Newport infection.

Formulas For Success: Abbott Touts Similarity To Breast Milk, ByHeart Promotes ‘Clean Label’

Infant nutrition giant Abbott extends its Similac line with its “closest formula to breast milk ever” while startup ByHeart approaches its initial launch with announcement its formula is first certified by  Clean Label Project.

Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel